润都股份：氢氯噻嗪获得化学原料药上市申请批准通知书

Core Viewpoint - The approval of hydrochlorothiazide as a chemical raw material drug by the National Medical Products Administration enhances the company's product portfolio and strengthens its market competitiveness, positively impacting future operating performance [1] Group 1 - The company received the approval notice for hydrochlorothiazide from the National Medical Products Administration [1] - The application for the domestic production of hydrochlorothiazide was submitted in April 2024 and accepted by the Center for Drug Evaluation [1] - The company completed supplementary research and submitted the required documentation by May 2025, leading to the approval in August 2025 [1] Group 2 - Hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and nephrolithiasis [1] - The approval of this product enriches the company's product categories and improves its full industry chain layout [1] - The new product is expected to have a positive impact on the company's future operating performance [1]